Remnant epitopes generate autoimmunity: from rheumatoid arthritis and multiple sclerosis to diabetes.

Autoimmune diseases are characterized by inflammation and by the development and maintenance of antibodies and T lymphocytes against "self" antigens. Although the etiology of these diseases is unknown, they have a number of cellular and molecular mechanisms in common. Pro-inflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor (TNF), are upregulated and activate the inflammatory process. Chemokines recruit and activate leukocytes to release proteases, including matrix metalloproteinases (MMPs). These proteases degrade proteins into remnant fragments, which often constitute immunodominant epitopes. Either by direct loading into major histocompatibility complex (MHC) molecules or after classical antigen uptake, processing and MHC presentation, these remnant epitopes are presented to autoreactive T lymphocytes. Also, posttranslationally modified remnant peptides may stimulate B cells to produce autoantibodies. This forms the basis of the "Remnant Epitopes Generate Autoimmunity" (REGA) model. We have documented evidences for this model in multiple sclerosis (MS), rheumatoid arthritis (RA) and diabetes, which are summarized here. Furthermore, three topics will be addressed to illustrate the importance of glycobiology in the pathogenesis of autoimmune diseases. In MS, gelatinase B or MMP-9 is a pathogenic glycoprotein of which the sugars contribute to its interactions with the tissue inhibitor of metalloproteinases-1 (TIMP-1) and thus assist in the determination of the enzyme activity. In RA, gelatinase B cleaves denatured type II collagen into remnant epitopes, some of which constitute immunodominant glycopeptides. This implies that immunodominant epitope scanning experiments should preferably be done with natural posttranslationally modified glycopeptides, rather than with unmodified (synthetic) peptides. Sugars can also be used as molecular probes to induce autoimmune diseases. One of the best examples is the induction of acute pancreatitis, insulitis and diabetes by streptozotocin. In addition, gelatinase B is upregulated in pancreatitis and cleaves insulin. The most efficient cleavage by gelatinase B leads to a major insulin remnant epitope.

[1]  R. Dwek,et al.  Glycosylation of natural human neutrophil gelatinase B and neutrophil gelatinase B-associated lipocalin. , 1999, Biochemistry.

[2]  T. Shimosegawa,et al.  Pancreatic diabetes in Japan. , 1998, Pancreas.

[3]  T. Tomita,et al.  Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[4]  W. Pangborn,et al.  Phase changes in T(3)R(3)(f) human insulin: temperature or pressure induced? , 2001, Acta crystallographica. Section D, Biological crystallography.

[5]  R. Dwek,et al.  Glycosylation: heterogeneity and the 3D structure of proteins. , 1997, Critical reviews in biochemistry and molecular biology.

[6]  G. Opdenakker,et al.  Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. , 1993, Biochemical and biophysical research communications.

[7]  L. Kotra,et al.  N-Glycosylation pattern of the zymogenic form of human matrix metalloproteinase-9. , 2002, Bioorganic chemistry.

[8]  C. Overall,et al.  Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. , 2000, Science.

[9]  L. Fugger,et al.  Predominant selection of T cells specific for the glycosylated collagen type II epitope (263–270) in humanized transgenic mice and in rheumatoid arthritis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  G. Opdenakker,et al.  Development and application of a radioimmunoassay for interleukin-8: detection of interleukin-8 in synovial fluids from patients with inflammatory joint disease. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[11]  R. Dwek,et al.  Glycosylation and the immune system. , 2001, Science.

[12]  G. Opdenakker,et al.  Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. , 1991, European journal of biochemistry.

[13]  P. E. Van den Steen,et al.  Gelatinase B: a tuner and amplifier of immune functions. , 2001, Trends in immunology.

[14]  A. Varki,et al.  Biological roles of oligosaccharides: all of the theories are correct , 1993, Glycobiology.

[15]  M. Coletta,et al.  Modulation of the Catalytic Activity of Neutrophil Collagenase MMP-8 on Bovine Collagen I , 2002, The Journal of Biological Chemistry.

[16]  D. Wegmann,et al.  Insulin‐specific T cells are a predominant component of islet infiltrates in pre‐diabetic NOD mice , 1994, European journal of immunology.

[17]  S. Chandran,et al.  Peripheral blood level alterations of TIMP‐1, MMP‐2 and MMP‐9 in patients with Type 1 diabetes , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[18]  R. Dwek,et al.  Glycoforms modify the dynamic stability and functional activity of an enzyme. , 1994, Biochemistry.

[19]  P. E. Van den Steen,et al.  Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  R. Sciot,et al.  Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. , 1999, The Journal of clinical investigation.

[21]  P. E. Van den Steen,et al.  Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post‐translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  D. Wegmann,et al.  It's insulin. , 2000, Journal of autoimmunity.

[23]  M. Lukic,et al.  Effector Mechanisms in Low-Dose Streptozotocin-induced Diabetes , 1998, Developmental immunology.

[24]  H. Mori,et al.  Stepwise Movement of Preproteins in the Process of Translocation across the Cytoplasmic Membrane of Escherichia coli(*) , 1995, The Journal of Biological Chemistry.

[25]  A. Rossini,et al.  Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. , 1976, Science.

[26]  T. Nakamura,et al.  Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  R. Dwek,et al.  O-glycan analysis of natural human neutrophil gelatinase B using a combination of normal phase-HPLC and online tandem mass spectrometry: implications for the domain organization of the enzyme. , 2000, Biochemistry.

[28]  G. Opdenakker,et al.  Cytokine-regulated proteases in autoimmune diseases. , 1994, Immunology today.

[29]  H. Iguchi,et al.  Clinical assessment of pancreatic diabetes caused by chronic pancreatitis , 1998, Journal of Gastroenterology.

[30]  R. Dwek,et al.  Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition , 1995, European journal of immunology.

[31]  G. Schneider,et al.  Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. , 1999, Science.

[32]  R. Dwek,et al.  Cells regulate the activities of cytokines by glycosylation , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  R. Dwek,et al.  Oligosaccharides of recombinant mouse gelatinase B variants. , 1998, Biochimica et biophysica acta.

[34]  R. Dwek,et al.  Recognition of carbohydrate by major histocompatibility complex class I- restricted, glycopeptide-specific cytotoxic T lymphocytes , 1994, The Journal of experimental medicine.

[35]  E. Unanue,et al.  Distinct recognition by two subsets of T cells of an MHC class II-peptide complex , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Dwek,et al.  Matrix remodelling enzymes, the protease cascade and glycosylation. , 2001, Biochimica et biophysica acta.

[37]  R. Dwek,et al.  Concepts and principles of O-linked glycosylation. , 1998, Critical reviews in biochemistry and molecular biology.

[38]  R. Dwek,et al.  The Activation of Type 1 and Type 2 Plasminogen by Type I and Type II Tissue Plasminogen Activator (*) , 1995, The Journal of Biological Chemistry.

[39]  E. Baker,et al.  Structure of Rhombohedral 2 Zinc Insulin Crystals , 1969, Nature.

[40]  P. E. Van den Steen,et al.  Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. , 2000, Blood.